School of Basic Medical Sciences, Guangzhou Νational Laboratory, Guangzhou Medical University, Guangzhou 511436, China ...

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, ...

The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...

Results: It was found that HDCA treatment of CRC cells was able to significantly inhibit the proliferative capacity of the cells. Furthermore, it was discovered that HDCA primarily stimulated ...

A study demonstrated that pharmacological activation of the farnesoid X receptor (FXR) in a mouse model could prevent PNAC by restoring liver function and reducing inflammation. This suggests that ...

It is administered through oral route. It acts by targeting farnesoid X receptor (FXR). The drug candidate was under development for primary sclerosing cholangitis in U.S. Cascade Pharmaceuticals is a ...

Preclinical studies suggest that bile acids can contribute to development of NAFL and NASH by altering nuclear bile acid receptor farnesoid X receptor (FXR) signalling.69 70 The primary bile acid ...

BAs are produced in the liver and metabolized by the GM in the intestine. Microbial modifications of BAs modulate host metabolism via BA receptors, such as the farnesoid X receptor (FXR) and the ...

LJN452 is Novartis’ most advanced of two Farnesoid X receptor (FXR) agonists. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Hughes states that ...

Expert Rev Cardiovasc Ther. 2008;6(3):391-409. Phosphatidic acid phosphatase/phosphohydrolase (PAP) is an enzyme that catalyzes the conversion of phosphatidic acid to ...

Gerdau S/A Ord 2.30% R$34.65B ...